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The explosive growth of mobile technologies combined with the rapid rise of aging populations
fearful of their risk for Alzheimer’s disease has led to a number of marketed products aimed
at enhancing cognitive health. However, an increasing number of product claims that are not
substantiated has led regulatory agencies, such as the Federal Trade Commission (FTC), to issue
warnings or penalties against some companies. Therefore, it is likely that a number of computerized
cognitive training (CCT) companies will conduct clinical trials to prove their efficacy to gain Food
and Drug Administration (FDA) clearance as a medical software/device. This raises a number
of issues such as optimal trial design for establishing efficacy. The type of control condition is
unique issue for CCT, given the variety of non-specific known to produce beneficial effects on
cognition that are difficult to isolate from the content of the program. These include participant
expectancy, engagement, motivation, novelty, and therapist interaction. We herein discuss the
types of non-specific factors, desirable qualities of an active control condition, and the nuances
that exist between previously used control conditions within the context of CCT for mild cognitive
impairment.
EXPECTANCY
One nonspecific factor is expectancy, which refers to the participant’s anticipation of positive or
negative treatment effects. Expectancies come in two major forms: outcome expectancy, which is
the belief that the treatment itself will result in a particular outcome, and response expectancy,
which is the participant’s subjective response to the treatment. Expectancies of both kinds impact
outcomes across modalities, including psychotherapy (Goossens et al., 2005; Smeets et al., 2008;
Weinberger, 2014), pharmacological interventions (Rutherford et al., 2010), and neurosurgery
(Freeman et al., 1999). Long known to produce clinically significant outcomes, the belief that one
will symptomatically improve is met with high response rates. For example, a meta-analysis of
randomized placebo-controlled trials of antidepressants found the placebo effect to be responsible
for the majority of observed change, in depression symptoms, with a response rate of 50% for those
receiving medications compared to 30% for groups assigned to the placebo condition (Walsh et al.,
2002).
Further evidence for the contribution of expectancy to treatment effectiveness can be found in
the different response rates across different trial designs. Greater response rates have been observed
in comparator trials between two drugs than in placebo-control trials in late-life depression (Sneed
et al., 2008). This discrepancy may be a consequence of participants in comparator trials knowing
they will receive treatment, while participants in placebo-controlled trials are hoping they are
assigned to the treatment arm (and hence have lower expectations). This finding has been extended
in middle-aged and adolescent depression (Rutherford et al., 2011) as well as in schizophrenia
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(Rutherford et al., 2014). Although these groups are diverse
in terms of presenting ailment, consistent among them is that
degree of expected improvement coincides with magnitude of
actual improvement.
Rutherford et al. (2010) elaborated on a model of expectancy
effects driving the differences in response rates between types of
trials in which the orbitofrontal cortex (OFC), rostral anterior
cingulate cortex (rACC), and nucleus accumbens (NAC) generate
and maintain expectancies (Rutherford et al., 2010). The OFC
and rACC are active during anticipation of pain and unpleasant
experiences (Petrovic et al., 2005). Placebos lower activation
of these regions which coincides with reduced severity of
experienced pain (Wager et al., 2004). This analgesic effect may
be partially explained by heightened opioid activity in the OFC
and rACC that follows placebo administration and correlates
with reported pain alleviation (Wager et al., 2007). Activation
of the NAC, on the other hand, occurs in anticipation of
reward. Greater activation of the NAC occurs with expectancy of
analgesia and is correlated with placebo-induced pain reduction
(Scott et al., 2007). Taken together, heightened expectancy of
relief attenuates appraisal of negative experiences to a clinically
significant degree.
In addition to altering perception of negative symptoms,
raising expectancy increases participant’s belief of self-efficacy
in their functioning, making them more confident in their own
capability to perform tasks. Judgments of high self-efficacy are
associated with greater exerted effort in the face of challenges,
as well as lengthened persistence (Bandura, 1982). A systematic
review of placebo responses found self-efficacy and locus of
control to be significant predictors of symptom improvement
(Horing et al., 2014). The impact of response expectancy on
cognition is particularly important in trials of CCT, given
the use of performance-based outcome measures. In trials of
CCT, participants are told that improvement in their cognitive
functions is possible as a benefit from their involvement in
the study. This creates an expectation of better performance
following training, which is known to create positive cognitive
outcomes. Indeed, participants who enrolled in a trial of CCT
via a flyer suggesting CCT will improve working memory and
fluid intelligence had greater post-training performance than
participants who enrolled via a non-suggestive flyer, despite
participating in the same program (Foroughi et al., 2016).
Similarly, in a trial of healthy adults randomly assigned to a
placebo pill or no-pill condition, those who took the placebo pill
described as a “cognitive enhancer” had greater performance on
tests of attention and delayed recall, though no effect was found in
five secondary outcome measures (Oken et al., 2008). Given the
potential effect of expectancy on cognitive performance, and the
wide use of neuropsychological tests as primary outcomes in CCT
trials, treatment, and comparison conditions must be balanced in
terms of anticipated improvement.
ENGAGEMENT
How well a CCT program captivates and sustains attention
will affect the capability of subjects to participate and focus
during training. How engaging a task is depends on numerous
factors, including usability, focused attention, positive affect,
esthetics, endurability, richness, and control (Wiebe et al., 2014).
These characteristics can be independent of the main program
content. For example, a 2-back task necessitates workingmemory
ability by nature of the design alone. By adding auditory
feedback, sound effects, colorful animations, score tracking, and
countdown timers, the task becomes more attractive to the
participant. Such design elements create a nonspecific cognitive
load, are not unique to CCT, yet make the CCT condition more
interesting than the comparison group. When comparing an
engaging CCT task to either waitlist or uninteresting control
activities, it becomes impossible to isolate the central treatment
effect.
MOTIVATION
Whereas engagement may be understood as emotional or
attentional investment during a task, motivation is a global
personal orientation to the activity (Wiebe et al., 2014). A
participant may believe that cognitive improvement is contingent
upon active involvement in their training. Numerous cognitive
training platforms track then share performance data with
participants. Following conclusion of a module, participants
are shown their score, typically alongside a report of previous
attempts. Congratulatory messages for surpassing earlier records
are common. This positive feedback and potential for goal-
setting behavior creates an environment where the participant is
motivated to perform well.
Participant’s beliefs about the malleability of their intelligence
will affect their performance as well. In a study evaluating
performance on tests of general knowledge, participants who
held the believe that intelligence is malleable corrected more
errors in their responses during retesting than participants
who believed that intelligence is fixed (Mangels et al., 2006).
When given negative feedback following errors, participants who
believed in fixed intelligence demonstrated reduced memory-
encoding activity in the temporal lobe. This suggests that
one’s attitude toward learning will affect the amount of effort
placed in training tasks. This is particularly important for
older adults with MCI, whose motivation toward the task may
be increased by the prospect of preventing further cognitive
decline.
NOVELTY
The novelty effect is the tendency for improved performance due
to interest in a fresh experience, rather than the content. A review
of educational research found that when not controlled, novelty
effects create an increase in test scores. On average, performance
increases due to novelty by 50% of a standard deviation for the
first 4 weeks, and by 20% of a standard deviation after 8 weeks
(Clark and Sugrue, 1991). Novel experiences may also simply
be remembered better than familiar ones. On tasks of explicit
recognition, subjects show higher accuracy in identifying novel
words from a studied list than familiar words viewed multiple
times (Tulving and Kroll, 1995; Habib et al., 2003). Given that
CCT consists of tasks not encountered in everyday life, and
prior familiarity with training protocols is grounds for excluding
participants, there is ample opportunity for sheer novelty of
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the task to constitute a considerable portion of any measured
effects.
ACTIVE CONTROLS
To address these issues, studies have employed active controls,
where the comparison condition completes an activity designed
to account for non-specific factors. This type of control condition
aims to determine whether the benefits of such mental exercise
are unique to CCT or can be obtained by any stimulating
activity. Commonly used active controls include crossword
puzzles, word searches, newspapers, and questionnaires. Active
controls alleviate ethical issues of placebo-controlled treatments,
as both the treatment and comparison condition may expect
improvement. Although active controls are methodologically
superior to waitlist conditions, differences in effect sizes between
active control conditions and passive control conditions are not
consistently observed (Karbach and Verhaeghen, 2014; Au et al.,
2015), and the nature of the active control task may not account
for all non-specific effects. Given the diversity of CCT paradigms
and quantity of non-specific factors, researchers have argued that
there is no universally applicable active control condition for all
design cases (Boot et al., 2013). Instead, the control condition
must be reasonably related to the tasks of the CCT condition
such that participants expect improvement in the same cognitive
domain regardless of their group assignment.
Table 1 contains a list of studies of CCT in patients with
mild cognitive impairment (MCI). Most studies use waitlist
control conditions (Rozzini et al., 2007; Finn and McDonald,
2011) or control conditions that do not account for engagement
and motivation in the task (Galante et al., 2007; Talassi et al.,
2007; Gagnon and Belleville, 2012; Herrera et al., 2012; Carretti
et al., 2013; Gaitan et al., 2013). In such designs, the treatment
condition is at an unfair advantage because patients assigned
to CCT have a greater chance of improvement simply because
the tasks are engaging and motivating whereas those assigned to
waitlist control lose interest and motivation. Even when active
control conditions have been used in previous studies of CCT
in MCI, they are not consistently computerized (Talassi et al.,
2007; Herrera et al., 2012; Carretti et al., 2013; Gaitan et al., 2013)
and consist of CCT tasks of invariable complexity (Gagnon and
Belleville, 2012; Gaitan et al., 2013). Comparing CCT that scales
in difficulty with participant performance to CCT that remains at
a fixed difficulty does not determine whether effects are specific
to CCT or can be obtained with any engaging computerized
game. Further, trials of scaling difficulty fail to take into account
the novelty of experience they introduce, beyond just harder
problems.
The CCT conditions themselves vary considerably, both by
targeted cognitive domains and whether they are administered
alone (Galante et al., 2007; Barnes et al., 2009; Finn and
McDonald, 2011; Rosen et al., 2011; Gagnon and Belleville, 2012;
Herrera et al., 2012; Carretti et al., 2013; Gooding et al., 2016),
or as part of a wider intervention (Rozzini et al., 2007; Talassi
et al., 2007; Gaitan et al., 2013). If CCT is administered alongside
additional therapies, the magnitude of participant’s expectancy,
engagement, and motivation may be greater than if they were
treated with CCT alone. Such nuances in design will impact the
magnitude of the observed differences between the training and
control groups, and the measured effect sizes across trials. One
needs to consider the nonspecific factors present in both the CCT
and control conditions in order to accurately interpret the results.
MODEL CONTROL CONDITIONS
An adequate comparison condition must be matched for
engagement, motivation, training time, computer interface, and
novelty of stimuli. Preferably, the control group should account
for nonspecific factors without introducing neurocognitive
demands. If it does create specific effects, their impact on
cognitive functioning should be known before comparing it
to a CCT group. By using a CCT group, an active control
group, and a passive control group, the relative contributions
of each nonspecific factor can be estimated (Greenwood and
Parasuraman, 2016). There is no “one size fits all” control
condition. Instead, the selection of a control condition must be
made in view of the content of the CCT platform and the specific
research question.
An example of a well-balanced active control condition
is a CCT program targeting domains of cognition that are
different from those being targeted in the CCT program of
the intervention condition. Should one group find greater
improvement in cognitive domains of interest that transfer to
untrained domains and quality of life, this can be taken as
evidence that the content of CCT matters more than the non-
specific factors. Participants in the active control group must
expect the same types of cognitive benefits as those in the training
group, principally by the control group and training group having
identical descriptions of anticipated effects.
Another active control condition is one that incorporates non-
adaptive versions of CCT. These programs use the same types of
tasks as those in the experimental training condition, though they
do not scale in difficulty with participant performance. When
compared with adaptive versions of the same procedure, the
tasks are balanced on participant expectancy and motivation,
and practice effects can be ruled out. However, scaling difficulty
introduces novelty, both in terms of activities encountered and
strategies necessary for completing the task. Further, participants
who complete the same task at unchanging difficulty may
become less engaged as they reach their peak performance early.
Controlling for practice effects is particularly important in older
adults with cognitive impairment, given their propensity toward
greater practice effects than their cognitively-stable peers (Suchy
et al., 2011).
Remedial skills training has also been used as an active
control condition. In these groups, participants discuss top-
down strategies aimed at compensating with cognitive deficits.
Such designs make it difficult to disentangle the plasticity of
representations (knowledge, skills) from plasticity of processes
(cognitive ability, brain function, brain structure, Fissler et al.,
2015). It is possible that improvement following CCT is due
to familiarity with neuropsychological tests and not due to
improvement in underlying cognitive capacities. For example,
learning to chunk numbers may improve digit span score, but
may reflect one’s ability to apply knowledge of cognitive strategies
rather than one’s actual attentional capacity. Comparisons
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TABLE 1 | Studies of CCT for MCI.
Study name Treatment condition Control condition Control Weaknesses
Barnes et al., 2009 Processing speed and auditory processing
CCT (n = 22)
Audio books, reading online newspapers,
visuospatial computer games (n = 25)
Heterogeneous control tasks, not
matched for engagement
Carretti et al., 2013 Working memory CCT (n = 10) Memory discussion and questionnaires
(n = 10)
Control group not computerized, unequal
socialization opportunities
Finn and McDonald, 2011 Attention, processing speed, visual memory,
and cognitive control CCT(n = 12)
Waitlist (n = 13) Non-active control condition
Gaitan et al., 2013 CCT + pen and paper cognitive training
(n = 37)
Pen and paper cognitive training (n = 23) Control group not computerized, not
matched for engagement
Galante et al., 2007 Attention, memory, language, abstract
reasoning, and visuo-spatial CCT (n = 7)
Life history and current event discussion
(n = 4)
Heterogeneous control tasks, not




Variable priority divided attention tasks (n = 13) Fixed priority variable attention tasks
(n = 13)
Does not account for engagement, novelty
Gooding et al., 2016 Milieu-based attention, memory, and executive
function CCT (n = 23) Attention, memory, and
executive function CCT (n = 31)
BrainAge, Sudoku, crosswords (n = 20) Heterogeneous control activities, different
CCT vs. control interface
Herrera et al., 2012 Short-term memory CCT (n = 11) Fact searching, crossing out letters,
sentence construction (n = 11)
Heterogeneous control tasks, not entirely
computerized, not matched for
engagement
Rosen et al., 2011 Processing speed and auditory processing
CCT (n = 6)
Audio books, reading online newspapers,
visuospatial computer games (n = 6)
Small sample size, heterogeneous control
tasks, not matched for engagement
Rozzini et al., 2007 Attention, memory, language, abstract
reasoning, and visuo-spatial CCT +
cholinesterase inhibitors (n = 15)
Cholinesterase inhibitors only (n = 22) And
Waitlist (n =22)
Non-active control condition
Talassi et al., 2007 CCT, occupational therapy, and behavioral
training (n = 54)
Physical rehabilitation, occupational
therapy, and behavioral training (n = 13)
Heterogeneous control tasks, not matched
for engagement, not computerized
between cognitive remediation and CCT are useful for balancing
expectancy, motivation, and novelty, but offer little insight into
the precise mechanism of any observed cognitive improvement.
LOOKING FORWARD
Future studies would benefit from inclusion of measures to
evaluate non-specific factors as covariates. For example, the User
Engagement Scalemeasures aspects of engagement, usability, and
satisfaction on a 5-point Likert scale and comprises both negative
(“I felt annoyed when on this site,” “the game was confusing”)
and positive (“I really had fun,” “It was really worthwhile”) items
(Wiebe et al., 2014). The Immersive Experience Questionnaire
provides ratings of temporal distortion, challenge, emotional
involvement, enjoyment, and attentional involvement in the task
(Jennett et al., 2008). Expectancy can be evaluated using the
Credibility and Expectancy Scale (Devilly and Borkovec, 2000).
The CES asks participants to report how logical the therapy
seems, how successful they expect the treatment to be, and
whether they would recommend the treatment to a friend. Two
factors, credibility, and expectancy, have been found within the
CES, with expectancy ratings successfully predicting treatment
outcome in a randomized controlled trial of cognitive therapies
for generalized anxiety disorders.
Until CCT can be found to improve cognitive and everyday
functioning after accounting for each non-specific factor, its
future as a treatment remains uncertain. What is more certain
is the usefulness of being generally mentally active. Indeed,
high levels of mental activity may be associated not only with
higher cognitive performance, but reduced risk of dementia. A
systematic review of 22 population studies foundmental exercises
may reduce overall incident dementia risk by 46% (Valenzuela
and Sachdev, 2006). Whether CCT is the same as any other form
of mental activity or represents a unique method for augmenting
cognitive processes shall be a continuing topic of investigation.
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